Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05371353 | Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine | recruiting | — | 600 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06354738 | Improving Endometrial Cancer Assessment by Combining Genomic Profiling and Surgical Assessment(EUGENIE) | recruiting | N/A | 1,000 | University Hospital, GasthuisbergOTHER | 1 | Apr 17, 2024 |
| clinicaltrials |
| NCT03732950 | Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer | active not recruiting | Phase 2 | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05905315 | Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC(VULCANIZE-II) | recruiting | Phase 2 | 98 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT04838899 | Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer | recruiting | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05080556 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer(ACTOv) | recruiting | Phase 2 | 80 | University College, LondonOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06354231 | DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06336187 | European Active Surveillance of Renal Cell Carcinoma Study (EASE RCC Study)(EASE) | recruiting | — | 400 | Azienda Ospedaliero Universitaria Maggiore della CaritaOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06358053 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | not yet recruiting | Phase 1 | 24 | Corregene Biotechnology Co., LtdINDUSTRY | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06355518 | Pre-operative Immuno-Nutrition in Radical Cystectomy(INu-RC) | not yet recruiting | N/A | 260 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06350825 | Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT05447273 | The Role of Functional Magnetic Resonance Imaging in Preoperative Assessment of Primary Penile Carcinoma | recruiting | — | 60 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06341478 | Investigator Grant (IG) 2022 27746 | recruiting | N/A | 153 | IRCCS San RaffaeleOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06315270 | To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer | not yet recruiting | — | 100 | The First Hospital of Jilin UniversityOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT06335693 | Adjuvant Hypofractionated Radiotherapy for Prostate Cancer | recruiting | N/A | 9 | Changhai HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06333821 | A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma | not yet recruiting | Phase 3 | 460 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Mar 27, 2024 | clinicaltrials |
| NCT06325423 | Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer | not yet recruiting | — | 50 | Assiut UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06329323 | SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours(SUMMER) | not yet recruiting | — | 24 | Imperial College LondonOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06330909 | Image-guided Focal Dose Escalation- Primary pc Treated With Primary External Beam Hypofract.Stereotactic rt(HypoF-SBRT) | recruiting | N/A | 374 | University Hospital FreiburgOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06320223 | PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer(PROMISE-PET) | recruiting | — | 10,000 | University Hospital, EssenOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06321679 | Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone(RESPECT) | recruiting | — | 40 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06318559 | Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention(RIDERS) | recruiting | N/A | 120 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05200988 | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC(Indi-Blade) | active not recruiting | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05116475 | Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases(ALADDIN) | recruiting | Phase 3 | 152 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05219734 | MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment(MARIA) | active not recruiting | — | 400 | Invitae CorporationINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06305832 | Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | recruiting | Phase 2 | 102 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06292897 | Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression(OBESITA'&PCa) | recruiting | — | 25 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT04612907 | Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer(Hypo-M1) | recruiting | N/A | 420 | Umeå UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04642027 | PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy(PERYTON) | recruiting | Phase 3 | 538 | University Medical Center GroningenOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06155396 | A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer | recruiting | Phase 2 | 116 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06206083 | Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis | recruiting | — | 64 | National Institute of CancerologíaOTHER_GOV | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06284031 | Cervical Cancer Brachytherapy With Interstitial Needles in 3 Fractions | recruiting | N/A | 56 | National University Hospital, SingaporeOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04340245 | Exploiting Risk-Based Risk Stratification in Early Prostate Cancer to Discriminate Progressors From Non-Progressors(RECONCILE) | active not recruiting | — | 60 | University College, LondonOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06270043 | Focal Therapy for Localized Prostate Cancer | recruiting | — | 500 | University of California, San DiegoOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06278506 | Resection or Ablation of Small Kidney Tumors(RESTART) | recruiting | N/A | 300 | Karolinska University HospitalOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04029714 | Prostate Cancer Active Surveillance Trigger Trial (PCASTT-UK): Comparing Current Practice for Men With Prostate Cancer on Active Surveillance (AS) to an AS Protocol With Standardised Triggers for Transitioning to Curative Treatment | active not recruiting | N/A | 195 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06272240 | Tumor Microenvironment in Ovarian Cancer(MICO) | recruiting | — | 50 | University of UdineOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT06269536 | Stress-reducing Intervention in Urothelial Carcinoma | recruiting | N/A | 50 | Comenius UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06271551 | Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy(ESTRACISE) | not yet recruiting | Phase 2 | 310 | Central Finland Hospital DistrictOTHER | 0 | Feb 21, 2024 | clinicaltrials |
| NCT06041555 | MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)(ISRAR) | recruiting | — | 600 | Hospices Civils de LyonOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06223295 | Effectiveness of Focal Therapy in Men With Prostate Cancer(ENFORCE) | recruiting | N/A | 356 | Radboud University Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06259123 | Neoadjuvant PSMA-RLT in Oligometastatic PCa | recruiting | Phase 2 | 10 | Medical University of ViennaOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT04909294 | Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma(STEREO-RML) | active not recruiting | N/A | 68 | Centre Georges Francois LeclercOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06255964 | A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 236 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Feb 13, 2024 | clinicaltrials |
| NCT06230549 | Adaptive Radiotherapy in Patients With Gynecological Tumors(ProART) | recruiting | N/A | 30 | University Hospital, EssenOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06251388 | A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer | recruiting | Phase 2 | 50 | West China Second University HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2024source: clinicaltrials